200 related articles for article (PubMed ID: 18812319)
1. Isolation of hyperactive mutants of mammalian target of rapamycin.
Ohne Y; Takahara T; Hatakeyama R; Matsuzaki T; Noda M; Mizushima N; Maeda T
J Biol Chem; 2008 Nov; 283(46):31861-70. PubMed ID: 18812319
[TBL] [Abstract][Full Text] [Related]
2. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
3. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
[TBL] [Abstract][Full Text] [Related]
4. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.
Copp J; Manning G; Hunter T
Cancer Res; 2009 Mar; 69(5):1821-7. PubMed ID: 19244117
[TBL] [Abstract][Full Text] [Related]
5. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
6. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation.
Wang L; Harris TE; Lawrence JC
J Biol Chem; 2008 Jun; 283(23):15619-27. PubMed ID: 18372248
[TBL] [Abstract][Full Text] [Related]
7. Growing knowledge of the mTOR signaling network.
Huang K; Fingar DC
Semin Cell Dev Biol; 2014 Dec; 36():79-90. PubMed ID: 25242279
[TBL] [Abstract][Full Text] [Related]
8. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
9. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2.
Li W; Petrimpol M; Molle KD; Hall MN; Battegay EJ; Humar R
Circ Res; 2007 Jan; 100(1):79-87. PubMed ID: 17110594
[TBL] [Abstract][Full Text] [Related]
11. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
12. MITF-MIR211 axis is a novel autophagy amplifier system during cellular stress.
Ozturk DG; Kocak M; Akcay A; Kinoglu K; Kara E; Buyuk Y; Kazan H; Gozuacik D
Autophagy; 2019 Mar; 15(3):375-390. PubMed ID: 30290719
[TBL] [Abstract][Full Text] [Related]
13. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
14. Monitoring mammalian target of rapamycin (mTOR) activity.
Ikenoue T; Hong S; Inoki K
Methods Enzymol; 2009; 452():165-80. PubMed ID: 19200882
[TBL] [Abstract][Full Text] [Related]
15. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
16. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly.
Kaizuka T; Hara T; Oshiro N; Kikkawa U; Yonezawa K; Takehana K; Iemura S; Natsume T; Mizushima N
J Biol Chem; 2010 Jun; 285(26):20109-16. PubMed ID: 20427287
[TBL] [Abstract][Full Text] [Related]
17. Targeting mTOR globally in cancer: thinking beyond rapamycin.
Shor B; Gibbons JJ; Abraham RT; Yu K
Cell Cycle; 2009 Dec; 8(23):3831-7. PubMed ID: 19901542
[TBL] [Abstract][Full Text] [Related]
18. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of mTOR function by a gain-of-function approach.
Ohne Y; Takahara T; Maeda T
Cell Cycle; 2009 Feb; 8(4):573-9. PubMed ID: 19182527
[TBL] [Abstract][Full Text] [Related]
20. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells.
Fuchs BC; Finger RE; Onan MC; Bode BP
Am J Physiol Cell Physiol; 2007 Jul; 293(1):C55-63. PubMed ID: 17329400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
